Application and recent advances in conventional biomarkers for the prognosis of papillary thyroid carcinoma
Authors:
Open Access
- 21 May 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1598934
Abstract
Cancer remains one of the most common and deadliest diseases worldwide. Among endocrine neoplasms, the incidence of thyroid malignancies has been rising in recent years. Papillary thyroid carcinoma (PTC), the most frequently observed histological subtype of thyroid cancer (THCA), typically yields favorable clinical outcomes for affected individuals. However, this has raised concerns about the overdiagnosis and underdetermination of the prognostic factors in PTC cases. As a result, researchers now advocate for patient stratification and tailored therapeutic approaches for PTC cases, with the goal of minimizing unnecessary surgical procedures and radioiodine treatments. These treatments can lead to clinical complications and impose avoidable physiological and psychological stress on patients. Multiple prognostic biomarkers have been identified for PTC, which play a critical role in predicting outcomes and informing treatment decisions. This review examines both established molecular tools and recent advancements in the determination of prognosis in in papillary thyroid carcinoma.Keywords
This publication has 103 references indexed in Scilit:
- Faculty Opinions recommendation of High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.2013
- Guilty as chargedCancer Cell, 2004
- BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2003
- Clinical Implication of Hot SpotBRAFMutation, V599E, in Papillary Thyroid CancersThe Journal of Clinical Endocrinology & Metabolism, 2003
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- RET/PTC Rearrangement in Thyroid TumorsEndocrine Pathology, 2002
- Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996Cancer, 2000
- Pathological Tumor-Node-Metastasis (pTNM) Staging for Papillary and Follicular Thyroid Carcinomas: A Retrospective Analysis of 700 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1997
- A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastasesNature, 1987